Bunazosin
From Self-sufficiency
| File:Bunazosin.png | |
| Systematic (IUPAC) name | |
|---|---|
|
1-(4-(4-amino-6,7-dimethoxyquinazolin-2-yl)-1,4-diazepan-1-yl)butan-1-one | |
| Identifiers | |
| CAS Number | 80755-51-7 |
| ATC code | none |
| PubChem | CID 2472 |
| Chemical data | |
| Formula | C19H27N5O3 |
| Molar mass | 373.44 g/mol[[Script error: No such module "String".]] |
| Script error: No such module "collapsible list". | |
Bunazosin (INN) is an alpha 1 antagonist. Bunazosin was initially developed to treat benign prostatic hyperplasia (BPH). It has been approved in Japan in a topical form to treat glaucoma. The mechanism of action is a reduction of aqueous outflow through the uveoscleral pathway resulting in lowering the intraocular pressure. It also may act to improve blood flow to the ocular nerve. Systemic Alpha-1 adrenergic receptor antagonists have been implicated in Intraoperative Floppy Iris Syndrome (IFIS). Bunazosin potentially could have the same effect but there has been no research to substantiate this as a risk for cataract surgery.
| 40px | This antihypertensive-related article is a stub. You can help ssf by expanding it. |
Categories:
- Pages with script errors
- Pages with broken file links
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Antihypertensive agent stubs
- Alpha blockers
- Phenol ethers
- Quinazolines
- Amides
- 1,4-diazepanes
- 2Fix
